Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended): A method for assessing the effectiveness of a drug therapy and the organ function of a subject using a single integrated test device, comprising the steps of:

performing at least two of (a), (b) and (c) as follows:

(a) applying a body fluid sample from the subject to a first test strip containing a signal-producing reagent system that produces a signal indicative of the concentration of an organ marker present in the sample,

using the first test strip with the single integrated test device having a means for detecting the signal produced by the first test strip and determining, therefrom, the concentration of the organ marker in the body fluid sample, and

displaying the concentration of the organ marker in the sample on a display of the single integrated test device;

(b) applying a body fluid sample from the subject to a second test strip containing a signal-producing reagent system that produces a signal indicative of the concentration of a drug present in the sample,

using the second test strip with the single integrated test device having a means for detecting the signal produced by the second test strip and determining, therefrom, the concentration of the drug in the body fluid sample, and

displaying the concentration of the drug in the sample on the display of the single integrated test device; and

(c) applying a body fluid sample from the subject to a third test strip containing a signal-producing reagent system that produces a signal indicative of the concentration of a metabolite present in the sample;

using the third test strip with the single integrated test device having a means for detecting the signal produced by the third test strip and determining, therefrom, the concentration of the metabolite in the body fluid sample, and

displaying the concentration of the metabolite in the sample on the display of the single integrated test device;

thereby providing for the assessment of [assessing] the subject's organ function and the therapeutic efficacy of the drug.

2. (Original): The method of claim 1, wherein steps (a) and (b) are performed, but not step (c).

3. (Original): The method of claim 1, wherein steps (a) and (c) are performed, but not step (b).

4. (Original): The method of claim 1, wherein steps (b) and (c) are performed, but not step (a).

5. (Original): The method of claim 1, wherein the organ marker is indicative of the function of an organ selected from the group consisting of liver and kidneys.

6. (Original): The method of claim 1, wherein the organ marker is selected from the group consisting of ALT, AST, GGT and creatinine.

7. (Original): The method of claim 6, wherein the organ marker is AST.

8. (Original): The method of claim 6, wherein the organ marker is ALT.

9. (Original): The method of claim, 1, wherein the drug causes damage to an organ selected from the group consisting of liver and kidneys.

10. (Original): The method of claim 1, wherein the drug is selected from the group consisting of troglitazone, metformin, phenformin, prednisone, prednisolone, docetazel, gemcitabine, biculutamide, nilutamide, isoniazi, methlydopa, nitrofurantoin, phenytoin, streptomycin, cimetidine, clofibrate, phentyoin, hydroclorothiazide, acetaminophen, ibuprofen and tolcapone.

11. (Original): The method of claim 10, wherein the drug is troglitazone.

12. (Original): The method of claim 10, wherein the drug is metformin.

13. (Original): The method of claim 1, wherein the metabolite is selected from the group consisting of glucose, fructosamine, hemoglobin A_{1c} {HbA_{1c}), lactic acid and creatinine.

14. (Original): The method of claim 13, wherein the metabolite is glucose.

15. (Original): The method of claim 13, wherein the metabolite is fructosamine.

Claims 16-20 (Canceled):